Kanceras vd avgår efter tuff tid för företaget

Peter Selin lämnar rollen som vd för Kancera, som byter namn till Novakand Pharma.

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”

It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...

Microscopy in Urinalysis: Observe Urine, Detect Abnormalities

Webinar on 18th March 2025, 10 AM - 11 AM CET.

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Danish obesity success causes recruitment problems in southern Sweden

The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Lifs Sofia Wallström tar plats i EFPIA:s styrelse

Lifs vd Sofia Wallström har valts in i styrelsen för den europeiska branschorganisationen EFPIA.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

J&J tar i från tårna – ska spendera 555 miljarder kronor

Under de kommande fyra åren ska Johnson & Johnson spendera 55 miljarder dollar i USA, motsvarande cirka 555 miljarder kronor.

Därför är SEO inte dött: “Viktigare än någonsin”

AI förändrar hur vi söker information – men grunden för att synas på nätet är densamma. För bolag inom biotech och life science är SEO särskilt viktigt: "Förtro...

FDA approves first non-opioid pain reliever in over 20 years

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Uppgifter: Sanofi tar in bud på konsumenthälsodivision

Den franska läkemedelsjätten Sanofi ska enligt uppgifter ha bett om initiala bud för sin konsumenthälsoverksamhet, som är värderad till runt 20 miljarder dollar.

Chiesi satsar på leverinriktad genterapi

Läkemedelsbolaget Chiesi tar ytterligare kliv in på genterapiområdet genom ett licensavtal med amerikanska Arbor Biotechnologies.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)

Efter förseningen – nu lämnar Xspray in uppdaterad FDA-ansökan

Forskningsbolaget Xspray Pharma har nu lämnat in en uppdaterad FDA-ansökan om godkännande för leukemibehandlingen Dasynoc.

Conference recordings now available

Don't miss out on insights from leading experts.